[PreS1 Antigen of HBV Down-Regulates MHC-Ⅰ on the Surface of Hepatocytes and Promotes Hepatocarcinogenesis]

Overview

Journal Sichuan Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2022 Mar 25

PMID 35332731

Authors

Jing-Jing Rao

Feng Zeng

Man-Shan Ji

Xiang Xu

Chun-Fang Yu

Jing Yang

Long Liu

Zhi-Xin Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the internal mechanism of hepatocellular carcinoma (HCC) induced by chronic hepatitis B virus (HBV) infection.

Methods: L02, HepG2 and Huh7 cells stably overexpressing HBV preS1 antigen were analyzed by flow cytometry, qRT-PCR and tumorigenesis in nude mice to evaluate the effect of preS1 antigen in HBV-related hepatocarcinogenesis.

Results: Our results showed that the expression of cancer stem cell (CSCs) related factors and cell surface markers in preS1 overexpressing cells were up-regulated, and the tumorigenicity of these cells was enhanced in nude mice. In addition, preS1 overexpression could down-regulate the expression of major histocompatibility complex Ⅰ (MHC-Ⅰ). The expression of MHC-Ⅰ on the cell surface could be restored by adding interferon gamma (IFN-γ) in the process of cell culturing and the tumorigenicity of cells in nude mice could thus be reduced.

Conclusion: Based on the above results, we believe that preS1 is a carcinogen of HBV and that it promotes the formation of liver cancer through down regulating MHC-Ⅰ on the surface of hepatocytes.

References

de Martel C, Maucort-Boulch D, Plummer M, Franceschi S . World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015; 62(4):1190-200. PMC: 5019261. DOI: 10.1002/hep.27969. View

Xu Z, Zhai L, Yi T, Gao H, Fan F, Li Y . Hepatitis B virus X induces inflammation and cancer in mice liver through dysregulation of cytoskeletal remodeling and lipid metabolism. Oncotarget. 2016; 7(43):70559-70574. PMC: 5342574. DOI: 10.18632/oncotarget.12372. View

Zong L, Peng H, Sun C, Li F, Zheng M, Chen Y . Breakdown of adaptive immunotolerance induces hepatocellular carcinoma in HBsAg-tg mice. Nat Commun. 2019; 10(1):221. PMC: 6333806. DOI: 10.1038/s41467-018-08096-8. View

Wang J, Michalak T . Inhibition by woodchuck hepatitis virus of class I major histocompatibility complex presentation on hepatocytes is mediated by virus envelope pre-S2 protein and can be reversed by treatment with gamma interferon. J Virol. 2006; 80(17):8541-53. PMC: 1563886. DOI: 10.1128/JVI.00830-06. View

Torresi J, Tran B, Christiansen D, Earnest-Silveira L, Schwab R, Vincan E . HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models. BMC Cancer. 2019; 19(1):707. PMC: 6637598. DOI: 10.1186/s12885-019-5916-6. View

Ferrandina G, Petrillo M, Bonanno G, Scambia G . Targeting CD133 antigen in cancer. Expert Opin Ther Targets. 2009; 13(7):823-37. DOI: 10.1517/14728220903005616. View

Kumar A, Bhanja A, Bhattacharyya J, Jaganathan B . Multiple roles of CD90 in cancer. Tumour Biol. 2016; 37(9):11611-11622. DOI: 10.1007/s13277-016-5112-0. View

Fatrai S, van Schelven S, Ubink I, Govaert K, Raats D, Koster J . Maintenance of Clonogenic KIT(+) Human Colon Tumor Cells Requires Secretion of Stem Cell Factor by Differentiated Tumor Cells. Gastroenterology. 2015; 149(3):692-704. DOI: 10.1053/j.gastro.2015.05.003. View

Chen Y, Cheng M, Tian Z . Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol. 2006; 3(5):373-8. View

10.

Yang L, Ye S, Zhao X, Ji L, Zhang Y, Zhou P . Molecular Characterization of HBV DNA Integration in Patients with Hepatitis and Hepatocellular Carcinoma. J Cancer. 2018; 9(18):3225-3235. PMC: 6160693. DOI: 10.7150/jca.26052. View

11.

Monk M, Holding C . Human embryonic genes re-expressed in cancer cells. Oncogene. 2002; 20(56):8085-91. DOI: 10.1038/sj.onc.1205088. View

12.

Liu Z, Dai X, Wang T, Zhang C, Zhang W, Zhang W . Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett. 2017; 400:149-160. DOI: 10.1016/j.canlet.2017.04.017. View

13.

Mao X, Tey S, Ko F, Kwong E, Gao Y, Ng I . C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. Cancer Lett. 2018; 444:60-69. DOI: 10.1016/j.canlet.2018.12.003. View

14.

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

15.

Zhou F . Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. Int Rev Immunol. 2009; 28(3-4):239-60. DOI: 10.1080/08830180902978120. View

16.

Mullath A, Krishna M . Hepatocellular carcinoma - time to take the ticket. World J Gastrointest Surg. 2019; 11(6):287-295. PMC: 6658361. DOI: 10.4240/wjgs.v11.i6.287. View

17.

Arzumanyan A, Reis H, Feitelson M . Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013; 13(2):123-35. DOI: 10.1038/nrc3449. View